Literature DB >> 24991710

Gamma knife radiosurgery for cerebellopontine angle meningiomas: a multicenter study.

Dale Ding1, Robert M Starke, Hideyuki Kano, Peter Nakaji, Gene H Barnett, David Mathieu, Veronica Chiang, Sacit B Omay, Judith Hess, Heyoung L McBride, Norissa Honea, John Y K Lee, Gazanfar Rahmathulla, Wendi A Evanoff, Michelle Alonso-Basanta, L Dade Lunsford, Jason P Sheehan.   

Abstract

BACKGROUND: Resection of cerebellopontine angle (CPA) meningiomas may result in significant neurological morbidity. Radiosurgery offers a minimally invasive alternative to surgery.
OBJECTIVE: To evaluate, in a multicenter cohort study, the outcomes of patients harboring CPA meningiomas who underwent Gamma Knife radiosurgery (GKRS).
METHODS: From 7 institutions participating in the North American Gamma Knife Consortium, 177 patients with benign CPA meningiomas treated with GKRS and at least 6 months radiologic follow-up were included for analysis. The mean age was 59 years and 84% were female. Dizziness or imbalance (48%) and cranial nerve (CN) VIII dysfunction (45%) were the most common presenting symptoms. The median tumor volume and prescription dose were 3.6 cc and 13 Gy, respectively. The mean radiologic and clinical follow-up durations were 47 and 46 months, respectively. Multivariate regression analyses were performed to identify the predictors of tumor progression and neurological deterioration.
RESULTS: The actuarial rates of progression-free survival at 5 and 10 years were 93% and 77%, respectively. Male sex (P = .014), prior fractionated radiation therapy (P = .010), and ataxia at presentation (P = .002) were independent predictors of tumor progression. Symptomatic adverse radiation effects and permanent neurological deterioration were observed in 1.1% and 9% of patients, respectively. Facial spasms at presentation (P = .007) and lower maximal dose (P = .011) were independently associated with neurological deterioration.
CONCLUSION: GKRS is an effective therapy for CPA meningiomas. Depending on the patient and tumor characteristics, radiosurgery can be an adjuvant treatment to initial surgical resection or a standalone procedure that obviates the need for resection in most patients.

Entities:  

Mesh:

Year:  2014        PMID: 24991710     DOI: 10.1227/NEU.0000000000000480

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  6 in total

1.  Tinnitus Management in Lateral Skull Base Lesions.

Authors:  Juan San Juan; Gregory J Basura
Journal:  J Neurol Surg B Skull Base       Date:  2018-11-30

2.  Small Cerebellopontine Angle Meningioma-Surgical Experience of 162 Patients and Literature Review.

Authors:  Jiyuan Bu; Pengjie Pan; Hui Yao; Weiyi Gong; Yuan Liu; Zhengquan Yu; Zhong Wang; Jiang Wu; Gang Chen
Journal:  Front Oncol       Date:  2020-10-09       Impact factor: 6.244

3.  Parameters influencing local control of meningiomas treated with radiosurgery.

Authors:  Tania Kaprealian; David R Raleigh; Penny K Sneed; Nima Nabavizadeh; Jean L Nakamura; Michael W McDermott
Journal:  J Neurooncol       Date:  2016-04-30       Impact factor: 4.130

4.  Cranial nerve outcomes after primary stereotactic radiosurgery for symptomatic skull base meningiomas.

Authors:  Andrew Faramand; Hideyuki Kano; Ajay Niranjan; Stephen A Johnson; Mohab Hassib; Kyung-Jae Park; Yoshio Arai; John C Flickinger; L Dade Lunsford
Journal:  J Neurooncol       Date:  2018-04-24       Impact factor: 4.130

5.  Hypofractionated high-energy proton-beam irradiation is an alternative treatment for WHO grade I meningiomas.

Authors:  Pavlos Vlachogiannis; Olafur Gudjonsson; Anders Montelius; Erik Grusell; Ulf Isacsson; Kristina Nilsson; Erik Blomquist
Journal:  Acta Neurochir (Wien)       Date:  2017-10-24       Impact factor: 2.216

Review 6.  Ten-year follow-up after Gamma Knife radiosurgery of meningioma and review of the literature.

Authors:  Bodo E Lippitz; Jiri Bartek; Tiit Mathiesen; Petter Förander
Journal:  Acta Neurochir (Wien)       Date:  2020-06-26       Impact factor: 2.216

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.